Cidara Therapeutics, Inc.
CDTX
Rank in Stocks
#3194
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Share Price
$221.38
Last synced: 2026-01-08
Market Cap
$5.61B
Change (1 day)
0.00%
Change (1 year)
114.47%
Country
US
Trade Cidara Therapeutics, Inc. (CDTX)
Category
Healthcare
Stock price history for Cidara Therapeutics, Inc. (CDTX)
Highest end of day price: $221.30 on 2026-01-01
Lowest end of day price: $300.77 on 2015-04-01
Lowest end of day price: $300.77 on 2015-04-01
Stock price history of Cidara Therapeutics, Inc. from 2015 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -17.55% |
| 2025 | 886.34% |
| 2024 | 47.58% |
| 2023 | 30.93% |
| 2022 | -59.17% |
| 2021 | -32.54% |
| 2020 | -21.59% |
| 2019 | -2.71% |
| 2018 | -62.52% |
| 2017 | -30.69% |
| 2016 | -35.78% |
| 2015 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $514.04 | 20.59% |
US
|
|
| $241.53 | 778.61% |
US
|
|
| $138.09 | -3.47% |
AU
|
|
| $813.37 | 16.03% |
CH
|
|
| $875.26 | 4.85% |
NL
|
